Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Klaus, Danika
PROTECT, NCT05476497: Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects	Recruiting	1	46	US	VLP Peanut, Placebo	Allergy Therapeutics	Peanut Allergy	10/25	10/25
NCT04543461: American Lung Association (ALA) Lung Health Cohort	Recruiting	N/A	4000	US		Johns Hopkins University, National Heart, Lung, and Blood Institute (NHLBI), American Lung Association, Stanford University	Lung Diseases	09/26	09/26
Alanis, Zitiali
C4951003, NCT04743141: Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine	Recruiting	3	200	Europe, US	Rimegepant (PF-07899801)	Pfizer	Acute Treatment of Migraine	06/27	06/27
NCT04649242 / 2020-003517-35: Randomized Study in Children and Adolescents With Migraine: Acute Treatment	Recruiting	3	2100	Europe, Canada, Japan, US, RoW	Rimegepant/BHV3000, Matching placebo	Pfizer	Pediatric Migraine	01/29	01/29
PROTECT, NCT05476497: Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects	Recruiting	1	46	US	VLP Peanut, Placebo	Allergy Therapeutics	Peanut Allergy	10/25	10/25